Nektar Therapeutics Q1 2023 Earnings Report $0.93 -0.01 (-1.35%) (As of 12/20/2024 05:23 PM ET) Earnings HistoryForecast Nektar Therapeutics EPS ResultsActual EPS-$0.25Consensus EPS -$0.26Beat/MissBeat by +$0.01One Year Ago EPSN/ANektar Therapeutics Revenue ResultsActual Revenue$21.59 millionExpected Revenue$20.60 millionBeat/MissBeat by +$990.00 thousandYoY Revenue GrowthN/ANektar Therapeutics Announcement DetailsQuarterQ1 2023Date5/9/2023TimeN/AConference Call ResourcesPress ReleaseNKTR Earnings HistoryConference Call AudioYour browser does not support the audio element. Listen Now.Powered by Why I'm telling friends to avoid gold stocks (Ad)Back in November, gold made a tiny move of 1.6%. But according to my backtesting by using a special type of gold trade, I would have seen a 141% gain in just a week. It happened again in March. Gold nudged up 1.2%. This time? A 104% overnight gain. And in June? A 1% gold move turned into a 74% gain in two weeks. Granted, there would have been smaller wins and those that did not work out, but you see, there's a reason I'm telling all my friends to hold off from buying gold or regular gold stocks right now. There's a more lucrative way to play the gold market as we enter a new breakout period. It's all about catching what I call "Acceleration Cycles."And if you’d like to get your hands on this, here you go, the complete breakdown. Nektar Therapeutics Earnings HeadlinesNektar Therapeutics CEO Robin Howard sells $131,649 in stockDecember 19 at 9:35 PM | investing.comNektar Therapeutics (NASDAQ:NKTR) & Aravive (NASDAQ:ARAV) Head to Head AnalysisDecember 17, 2024 | americanbankingnews.comYour chance to get on the next “60-Second Trade”Ever heard of the “60-Second Trade”? It’s a unique cash flow strategy that lets regular traders target anywhere from $100 to a couple of thousand in extra cash flow in as little as 7 days… In on Monday, out on Friday!December 21, 2024 | WealthPress (Ad)Research Analysts Offer Predictions for NKTR FY2024 EarningsDecember 13, 2024 | americanbankingnews.comPromising Future for Nektar Therapeutics: Innovative Approach in Autoimmune Disease Treatment with RezpegaldesleukinDecember 12, 2024 | markets.businessinsider.comQ1 Earnings Forecast for NKTR Issued By HC WainwrightDecember 12, 2024 | americanbankingnews.comSee More Nektar Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Nektar Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Nektar Therapeutics and other key companies, straight to your email. Email Address About Nektar TherapeuticsNektar Therapeutics (NASDAQ:NKTR), a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.View Nektar Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Upcoming Earnings Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
